Purpose:Colorectal cancer (CRC) patients who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines of treatment the molecular landscape of resistant tumors must be ascertained. We investigated the role of mutations in the EGFR signalling axis on the acquisition of resistance to cetuximab in patients and cellular models. Experimental Design:Tissue samples were obtained from 37 CRC patients who became refractory to cetuximab. CRC cells sensitive to cetuximab were treated until resistant derivatives emerged. Mutational profiling of biopsies and cell lines was performed. Structural modeling and functional analyses were performed to causally associate the alleles to resistance. Results:The genetic profile of tumor specimens obtained after cetuximab treatment revealed the emergence of a complex pattern of mutations in EGFR, KRAS, NRAS, BRAF and PIK3CA genes, including two novel EGFR ectodomain mutations (R451C and K467T). Mutational profiling of cetuximab resistant cells recapitulated the molecular landscape observed in clinical samples and revealed three additional EGFR alleles: S464L, G465R and I491M. Structurally, these mutations are located in the cetuximab-binding region, except for the R451C mutant. Functionally, EGFR ectodomain mutations prevent binding to cetuximab but a subset is permissive for interaction with panitumumab. Conclusions:Colorectal tumors evade EGFR blockade by constitutive activation of downstream signalling effectors and through mutations affecting receptor-antibody binding. Both mechanisms of resistance may occur concomitantly. Our data have implications for designing additional lines of therapy for CRC patients who relapse upon treatment with anti-EGFR antibodies.

Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer

ARENA, Sabrina;SIRAVEGNA, GIULIA;LAZZARI, LUCA;RUSSO, MARIANGELA;DI NICOLANTONIO, Federica;BARDELLI, Alberto;
2015

Abstract

Purpose:Colorectal cancer (CRC) patients who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines of treatment the molecular landscape of resistant tumors must be ascertained. We investigated the role of mutations in the EGFR signalling axis on the acquisition of resistance to cetuximab in patients and cellular models. Experimental Design:Tissue samples were obtained from 37 CRC patients who became refractory to cetuximab. CRC cells sensitive to cetuximab were treated until resistant derivatives emerged. Mutational profiling of biopsies and cell lines was performed. Structural modeling and functional analyses were performed to causally associate the alleles to resistance. Results:The genetic profile of tumor specimens obtained after cetuximab treatment revealed the emergence of a complex pattern of mutations in EGFR, KRAS, NRAS, BRAF and PIK3CA genes, including two novel EGFR ectodomain mutations (R451C and K467T). Mutational profiling of cetuximab resistant cells recapitulated the molecular landscape observed in clinical samples and revealed three additional EGFR alleles: S464L, G465R and I491M. Structurally, these mutations are located in the cetuximab-binding region, except for the R451C mutant. Functionally, EGFR ectodomain mutations prevent binding to cetuximab but a subset is permissive for interaction with panitumumab. Conclusions:Colorectal tumors evade EGFR blockade by constitutive activation of downstream signalling effectors and through mutations affecting receptor-antibody binding. Both mechanisms of resistance may occur concomitantly. Our data have implications for designing additional lines of therapy for CRC patients who relapse upon treatment with anti-EGFR antibodies.
21
9
2157
2166
http://clincancerres.aacrjournals.org/content/early/2015/01/24/1078-0432.CCR-14-2821.abstract
Epidermal Growth Factor Receptor (EGFR); Anti-EGFR antibodies; EGFR mutation; colorectal cancer; cetuximab; panitumumab; oncogenic mutations
S. Arena; B. Bellosillo; G. Siravegna; A. Martinez; I. Canadas; L. Lazzari; N. Ferruz; M. Russo; S. Misale; I. Gonzalez; M. Iglesias; E. Gavilan; G. Corti; S. Hobor; G. Crisafulli; M. Salido; J. Sanchez; A. Dalmases; J. Bellmunt; G.D. Fabritiis; A. Rovira; F. Di Nicolantonio; J. Albanell; A. Bardelli; C. Montagut
File in questo prodotto:
File Dimensione Formato  
Arena_EGFRmutations_CCR_2015_postprint.pdf

embargo fino al 27/01/2016

Descrizione: Articolo principale corredato di dati supplementari
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.78 MB
Formato Adobe PDF
1.78 MB Adobe PDF Visualizza/Apri
2015_Arena_ClinCanRes_Article&SI.pdf

non disponibili

Descrizione: Articolo principale (PDF Editoriale) e dati supplementari
Tipo di file: PDF EDITORIALE
Dimensione 1.41 MB
Formato Adobe PDF
1.41 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1508090
Citazioni
  • ???jsp.display-item.citation.pmc??? 102
  • Scopus 172
  • ???jsp.display-item.citation.isi??? 160
social impact